Michael Andrew Chambers is Director at Sarepta Therapeutics, Inc. (SRPT). They have made 6 open-market trades across 1 company since 2022, most recently 2026-06-04.
CIK 0001932527
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $40.9M since 2022, never a sale. Across 6 scored buys the stock is down 15.7% at ninety days, and 15.7 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SRPT | 27,535 | $471K |
Shares reported on the most recent Form 4, priced at the 2026-06-05 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 83% | 33% |
| Avg Move | +1.8% | +2.9% | -15.7% |
| Alpha | +3.8% | +4.3% | -15.7% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SRPT | BUY | 2024-08-16 | 2024-08-20 | $133.80 | $9.9M | -3.9% | -10.0% | -25.9% |
| SRPT | BUY | 2023-08-14 | 2023-08-15 | $109.47 | $2.2M | +5.3% | +5.9% | -29.5% |
| SRPT | BUY | 2023-08-11 | 2023-08-14 | $108.05 | $5.1M | +2.9% | +5.5% | -29.3% |
| SRPT | BUY | 2023-08-10 | 2023-08-11 | $106.15 | $7.4M | +6.0% | +9.6% | -26.7% |
| SRPT | BUY | 2022-09-14 | 2022-09-15 | $104.39 | $11.3M | -1.4% | +4.2% | +15.0% |
| SRPT | BUY | 2022-08-19 | 2022-08-22 | $108.28 | $5.0M | +2.1% | +2.1% | +2.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.